Home Microbiology Antibiotics chemical Meropenem

research use only

Meropenem Antibiotics chemical

Cat.No.S1381

Meropenem (SM 7338) is an ultra-broad spectrum injectable antibiotic. This compound is used to treat a variety of bacterial infections. It is effective against both Gram-positive and Gram-negative bacteria. This chemical is often reserved for severe or high-risk cases due to its broad activity.
Meropenem Antibiotics chemical Chemical Structure

Chemical Structure

Molecular Weight: 383.46

Jump to

Quality Control

Batch: Purity: 99.08%
99.08

Solubility

In vitro
Batch:

Water : 77 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 383.46 Formula

C17H25N3O5S

 Storage (From the date of receipt)
CAS No. 96036-03-2 Download SDF Storage of Stock Solutions

Synonyms SM 7338 SMILES CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)O)C(C)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro
Meropenem has an antibacterial spectrum which is broadly similar to that of imipenem but, whilst slightly less active against staphylococci and enterococci, it is more active against Pseudomonas aeruginosa, all Enterobacteriaceae and Haemophilus influenzae. This compound is two- to four-fold more active than imipenem against Gram-negative organisms and its spectrum of antimicrobial activity is wider than those of all other drugs tested. Its MICs are not significantly influenced by high inocula and the drug is generally bactericidal. It demonstrates antagonism with several other beta-lactams against strains producing Type I cephalosporinases. This antibiotic binds most strongly to penicillin-binding protein 2 of Escherichia coli and Pseudomonas aeruginosa, and to penicillin-binding proteins 1 of Staphylococcus aureus. This chemical is a new carbapenem antibiotic which differs chemically from imipenem/cilastatin by having a 1-beta-methyl substitution, providing it with excellent intrinsic stability to human renal dehydropeptidase-I. It has one identified metabolite, a beta-lactam ring-opened form which is devoid of microbiological activity.
In vivo
Meropenem significantly increases the plamsa total clearance of valproate to about 1.5 times the control (6.09 mL/min/kg vs. 4.28 mL/min/kg) in rabbits. This compound significantly increases the urinary excretion of valproate- glucuronide in rabbits.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/7652497/
  • [5] https://pubmed.ncbi.nlm.nih.gov/11683247/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-12)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07759453 NOT_YET_RECRUITING
Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
IRCCS Azienda Ospedaliero-Universitaria di Bologna
 2026-10-01 PHASE3
NCT07004049 RECRUITING
Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection; Multidrug Resistance
National University of Singapore
 2025-04-21 PHASE4
NCT06184659 RECRUITING
Sepsis; Septic Shock
Scandinavian Critical Care Trials Group
 2025-06-26 PHASE4
NCT07556107 RECRUITING
Infection; Acute Kidney Injury; Sepsis
Bassett Healthcare
 2026-08-17 PHASE4
NCT07327619 RECRUITING
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Qilu Pharmaceutical Co., Ltd.
 2026-01-22 PHASE3
NCT07484633 NOT_YET_RECRUITING
Infection; Sepsis; NICU; PICU; Beta Lactams
Semmelweis University
 2026-04 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.